Status:
COMPLETED
Atomoxetine and Huntington's Disease
Lead Sponsor:
University of Iowa
Collaborating Sponsors:
Eli Lilly and Company
Conditions:
Huntington Disease
Chorea
Eligibility:
All Genders
18-65 years
Phase:
PHASE2
Brief Summary
The purpose of this research study is to evaluate the effect of atomoxetine (also known as Strattera) compared to placebo (inactive substance) on daily activities such as attention and focus, thinking...
Detailed Description
No medications have been investigated to improve attention and executive functions in patients with Huntington's disease, despite the evidence that these cognitive domains can be abnormal even before ...
Eligibility Criteria
Inclusion
- Confirmed Huntington's disease (HD) diagnosis
- Age 18 to 65
- Must have mild HD
- Must have complaints of poor attention
Exclusion
- Childhood history of attention deficit hyperactivity disorder (ADHD) symptoms
- Diagnosis of schizophrenia, bipolar affective disorder, dementia, delirium or severe anxiety
- Current use of a monoamine oxidase inhibitor (MAOI) medication
- Pregnancy
- Uncontrolled hypertension
- Tachycardia
- Cardiovascular or cerebrovascular disease
- History of a loss of consciousness for greater than (or equal to) 5 minutes
- Having any neurological disorder or insult other than Huntington disease
Key Trial Info
Start Date :
November 1 2005
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
February 1 2008
Estimated Enrollment :
20 Patients enrolled
Trial Details
Trial ID
NCT00368849
Start Date
November 1 2005
End Date
February 1 2008
Last Update
December 20 2012
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
The University of Iowa
Iowa City, Iowa, United States, 52242